NASDAQ:HALO - Halozyme Therapeutics Stock Price, Forecast & News

Halozyme Therapeutics trades on the NASDAQ under the ticker symbol "HALO."

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its quarterly earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.05. The biopharmaceutical company earned $46.20 million during the quarter, compared to the consensus estimate of $54.96 million. Halozyme Therapeutics had a negative net margin of 19.73% and a negative return on equity of 15.76%. The company's quarterly revenue was up 80.5% on a year-over-year basis. During the same quarter last year, the firm posted ($0.19) EPS. View Halozyme Therapeutics' Earnings History.

Halozyme Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 20th 2020. View Earnings Estimates for Halozyme Therapeutics.

Halozyme Therapeutics issued an update on its FY20 earnings guidance on Tuesday, January, 14th. The company provided earnings per share guidance of $0.60-0.70 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.56. The company issued revenue guidance of $230-245 million, compared to the consensus revenue estimate of $224.10 million.

5 analysts have issued 12 month price objectives for Halozyme Therapeutics' shares. Their forecasts range from $16.00 to $27.00. On average, they expect Halozyme Therapeutics' share price to reach $22.40 in the next year. This suggests a possible upside of 17.5% from the stock's current price. View Analyst Price Targets for Halozyme Therapeutics.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Halozyme Therapeutics.

Headlines about HALO stock have been trending extremely negative recently, according to InfoTrie. The research group scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Halozyme Therapeutics earned a news impact score of -4.5 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the immediate future. View News Stories for Halozyme Therapeutics.

Some companies that are related to Halozyme Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Micron Technology (MU), Allergan (AGN), Gilead Sciences (GILD) and Aegean Marine Petroleum Network (ANW).

Halozyme Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Campbell & CO Investment Adviser LLC (0.08%), Strs Ohio (0.04%), TIAA FSB (0.04%), Nisa Investment Advisors LLC (0.01%) and Zurcher Kantonalbank Zurich Cantonalbank (0.01%). Company insiders that own Halozyme Therapeutics stock include Dimitrios Chondros and Randal J Kirk. View Institutional Ownership Trends for Halozyme Therapeutics.

HALO stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio. View Insider Buying and Selling for Halozyme Therapeutics.

HALO stock was purchased by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC, TIAA FSB, Zurcher Kantonalbank Zurich Cantonalbank and Nisa Investment Advisors LLC. View Insider Buying and Selling for Halozyme Therapeutics.

Shares of HALO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of HALO stock can currently be purchased for approximately $19.07.

Halozyme Therapeutics has a market capitalization of $2.79 billion and generates $151.86 million in revenue each year. The biopharmaceutical company earns $-80,330,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis. Halozyme Therapeutics employs 281 workers across the globe.View Additional Information About Halozyme Therapeutics.

The official website for Halozyme Therapeutics is http://www.halozyme.com/.

Halozyme Therapeutics' mailing address is 11388 SORRENTO VALLEY ROAD, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-794-8889 or via email at [email protected]